Adalimumab for Ocular Inflammation

Khayyam Durrani, John H. Kempen, Gui shuang Ying, R. Oktay Kacmaz, Pichaporn Artornsombudh, James (Jim) Rosenbaum, Eric Suhler, Jennifer E. Thorne, Douglas A. Jabs, Grace A. Levy-Clarke, Robert B. Nussenblatt, C. Stephen Foster, Research Group SITE Research Group

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Mar 21 2016

Fingerprint

Inflammation
Eye Diseases
Visual Acuity
Scleritis
Anterior Uveitis
Prednisone
Adalimumab
Adrenal Cortex Hormones
Therapeutics

Keywords

  • Adalimumab
  • Humira
  • ocular inflammatory disease
  • scleritis
  • TNF-α antibody
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

Durrani, K., Kempen, J. H., Ying, G. S., Kacmaz, R. O., Artornsombudh, P., Rosenbaum, J. J., ... SITE Research Group, R. G. (Accepted/In press). Adalimumab for Ocular Inflammation. Ocular Immunology and Inflammation, 1-8. https://doi.org/10.3109/09273948.2015.1134581

Adalimumab for Ocular Inflammation. / Durrani, Khayyam; Kempen, John H.; Ying, Gui shuang; Kacmaz, R. Oktay; Artornsombudh, Pichaporn; Rosenbaum, James (Jim); Suhler, Eric; Thorne, Jennifer E.; Jabs, Douglas A.; Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Foster, C. Stephen; SITE Research Group, Research Group.

In: Ocular Immunology and Inflammation, 21.03.2016, p. 1-8.

Research output: Contribution to journalArticle

Durrani, K, Kempen, JH, Ying, GS, Kacmaz, RO, Artornsombudh, P, Rosenbaum, JJ, Suhler, E, Thorne, JE, Jabs, DA, Levy-Clarke, GA, Nussenblatt, RB, Foster, CS & SITE Research Group, RG 2016, 'Adalimumab for Ocular Inflammation', Ocular Immunology and Inflammation, pp. 1-8. https://doi.org/10.3109/09273948.2015.1134581
Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JJ et al. Adalimumab for Ocular Inflammation. Ocular Immunology and Inflammation. 2016 Mar 21;1-8. https://doi.org/10.3109/09273948.2015.1134581
Durrani, Khayyam ; Kempen, John H. ; Ying, Gui shuang ; Kacmaz, R. Oktay ; Artornsombudh, Pichaporn ; Rosenbaum, James (Jim) ; Suhler, Eric ; Thorne, Jennifer E. ; Jabs, Douglas A. ; Levy-Clarke, Grace A. ; Nussenblatt, Robert B. ; Foster, C. Stephen ; SITE Research Group, Research Group. / Adalimumab for Ocular Inflammation. In: Ocular Immunology and Inflammation. 2016 ; pp. 1-8.
@article{fc6e0a6da0344a36b27e237b31b68f0c,
title = "Adalimumab for Ocular Inflammation",
abstract = "Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47{\%}), and scleritis, occurring in 9 patients (28{\%}). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47{\%}) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50{\%}). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.",
keywords = "Adalimumab, Humira, ocular inflammatory disease, scleritis, TNF-α antibody, uveitis",
author = "Khayyam Durrani and Kempen, {John H.} and Ying, {Gui shuang} and Kacmaz, {R. Oktay} and Pichaporn Artornsombudh and Rosenbaum, {James (Jim)} and Eric Suhler and Thorne, {Jennifer E.} and Jabs, {Douglas A.} and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Foster, {C. Stephen} and {SITE Research Group}, {Research Group}",
year = "2016",
month = "3",
day = "21",
doi = "10.3109/09273948.2015.1134581",
language = "English (US)",
pages = "1--8",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Adalimumab for Ocular Inflammation

AU - Durrani, Khayyam

AU - Kempen, John H.

AU - Ying, Gui shuang

AU - Kacmaz, R. Oktay

AU - Artornsombudh, Pichaporn

AU - Rosenbaum, James (Jim)

AU - Suhler, Eric

AU - Thorne, Jennifer E.

AU - Jabs, Douglas A.

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Foster, C. Stephen

AU - SITE Research Group, Research Group

PY - 2016/3/21

Y1 - 2016/3/21

N2 - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

AB - Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

KW - Adalimumab

KW - Humira

KW - ocular inflammatory disease

KW - scleritis

KW - TNF-α antibody

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=84961390336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961390336&partnerID=8YFLogxK

U2 - 10.3109/09273948.2015.1134581

DO - 10.3109/09273948.2015.1134581

M3 - Article

C2 - 27003323

AN - SCOPUS:84961390336

SP - 1

EP - 8

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -